Zymeworks Inc.
ZYME- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937653
No open-market purchases or sales by Zymeworks Inc. insiders were filed in the last 90 days; 202 institutions reported holding it in 13F filings for Q2 2026, worth $1.82B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −6 vs. previous quarter
- 202
- 13F valueReported value at the end of Q2 2026
- $1.82B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ZYME, Q2 2026
No superinvestor reported holding ZYME at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Zymeworks Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2026 (view filing) | Jan 12 | 1 day | Hollywood MarkEVP & Chief Operating Officer | SSale | −6.12K | $22.67 | −$138.7K | −4.4%132.9K after | |
| Jan 12, 2026 (view filing) | Jan 12 | Same day | Smith Jeffrey T LEVP & Chief Medical Officer | SSale | −9.31K | $22.67 | −$211.1K | −25.8%26.7K after | |
| Jan 12, 2026 (view filing) | Jan 12 | Same day | Moore Paul AndrewChief Scientific Officer | SSale | −9.56K | $22.67 | −$216.7K | −16.5%48.5K after | |
| Jan 12, 2026 (view filing) | Jan 12 | Same day | Galbraith KennethChair & CEO | SSale | −30.4K | $22.67 | −$689.7K | −11.8%226.8K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Smith Jeffrey T LEVP & Chief Medical Officer | SSale | −10.5K | $25.10 | −$264.5K | −36.5%18.4K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Galbraith KennethChair & CEO | SSale | −54.3K | $25.10 | −$1.36M | −21.9%193.3K after | 2 lots |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Moore Paul AndrewChief Scientific Officer | SSale | −20.1K | $25.10 | −$504.8K | −33.2%40.4K after | 2 lots |
| Dec 22, 2025 (view filing) | Dec 22 | Same day | Galbraith KennethChair & CEO | SSale | −47.5K | $27.02 | −$1.28M | −26.3%133.3K after | |
| May 19, 2025 (view filing)6:35 PM ET | May 15-19 | 4 days | Nodelman Oleg and 1 otherDirector, 10% Owner | PPurchase | +55.4K | $11.47 | +$635.6K | +0.3%17.9M after | 2 lots |
| Apr 18, 2025 (view filing)3:17 PM ET | Apr 16-17 | 2 days | Nodelman Oleg and 1 otherDirector, 10% Owner | PPurchase | +128.7K | $11.32 | +$1.46M | +0.7%17.8M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Zymeworks Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | $600.4M | 29.77% | 00.0% | Unchanged |
| Rubric Capital Management LP | 7,000,000 | $183.0M | 1.68% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,251,030 | $111.1M | 0.00% | −302,858−6.7% | Reduced |
| Perceptive Advisors LLC | 4,182,953 | $109.3M | 1.70% | +672,875+19.2% | Added |
| BVF Inc | 3,649,142 | $95.4M | 2.44% | −85,000−2.3% | Reduced |
| Assenagon Asset Management S.A. | 2,504,054 | $65.5M | 0.04% | +1,776,068+244.0% | Added |
| Morgan Stanley | 2,231,260 | $58.3M | 0.00% | −249,308−10.1% | Reduced |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,781,116 | $46.6M | 0.05% | −126,923−6.7% | Reduced |
| Vanguard Capital Management LLC | 1,558,998 | $40.8M | 0.00% | −146,582−8.6% | Reduced |
| Nextech Invest, Ltd. | 1,113,946 | $29.1M | 1.38% | 00.0% | Unchanged |